Sodium Chloride Supplementation Is Not Routinely Performed in the Majority of German and Austrian Infants with Classic Salt-Wasting Congenital Adrenal Hyperplasia and Has No Effect on Linear Growth and Hydrocortisone or Fludrocortisone Dose

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • Walter Bonfig - , Klinikum Wels - Grieskirchen GmbH, Technische Universität München (Autor:in)
  • Friedhelm Roehl - , Otto-von-Guericke-Universität Magdeburg (Autor:in)
  • Stefan Riedl - , Universität Wien (Autor:in)
  • Jürgen Brämswig - , Westfälische Wilhelms-Universität Münster (Autor:in)
  • Annette Richter-Unruh - , Westfälische Wilhelms-Universität Münster (Autor:in)
  • Susanne Fricke-Otto - , Helios Kliniken Gruppe (Autor:in)
  • Angela Hübner - , Klinik und Poliklinik für Kinder- und Jugendmedizin, Universitätsklinikum Carl Gustav Carus Dresden, Technische Universität Dresden (Autor:in)
  • Markus Bettendorf - , Universität Heidelberg (Autor:in)
  • Eckhard Schönau - , Universität zu Köln (Autor:in)
  • Helmut Dörr - , Friedrich-Alexander-Universität Erlangen-Nürnberg (Autor:in)
  • Reinhard W. Holl - , Universität Ulm (Autor:in)
  • Klaus Mohnike - , Otto-von-Guericke-Universität Magdeburg (Autor:in)

Abstract

Sodium chloride supplementation in saltwasting congenital adrenal hyperplasia (CAH) is generally recommended in infants, but its implementation in routine care is very heterogeneous. Objective: To evaluate oral sodium hloride supplementation, growth, and hydrocortisone and fludrocortisone dose in infants with salt-wasting CAH due to 21-hydroxylase in 311 infants from the AQUAPE CAH database. Results: Of 358 patients with classic CAH born between 1999 and 2015, 311 patients had salt-wasting CAH (133 females, 178 males). Of these, 86 patients (27.7%) received oral sodium chloride supplementation in a mean dose of 0.9± 1.4 mmol/kg/day (excluding nutritional sodium content) during the first year of life. 225 patients (72.3%) were not treated with sodium chloride. The percentage of sodium chloride-supplemented patients rose from 15.2% in children born 1999-2004 to 37.5% in children born 2011- 2015. Sodium chloride-supplemented and -unsupplemented infants did not significantly differ in hydrocortisone and fludrocortisone dose, target height-corrected height-SDS.

Details

OriginalspracheEnglisch
Seiten (von - bis)7-12
Seitenumfang6
FachzeitschriftHormone Research in Paediatrics
Jahrgang89
Ausgabenummer1
PublikationsstatusVeröffentlicht - 1 Feb. 2018
Peer-Review-StatusJa

Externe IDs

PubMed 29073619

Schlagworte

Ziele für nachhaltige Entwicklung

Schlagwörter

  • Congenital adrenal hyperplasia, Fludrocortisone, Hydrocortisone, Salt-wasting congenital adrenal hyperplasia, Sodium chloride supplementation